Mizuho lowered the firm’s price target on Medtronic (MDT) to $98 from $100 and keeps an Outperform rating on the shares. The firm says the diabetes spinoff is designed to improve the company’s’ earnings growth profile. It believes Medtronic’s stock discount “still looks too steep considering multiple growth shots on goal potential” from the portfolio.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $92 from $94 at Baird
- Medtronic Reports Strong FY25 Results and Dividend Increase
- Medtronic’s Strong Financial Performance and Promising Growth Outlook Justify Buy Rating
- Medtronic’s Mixed Outlook: Hold Rating Amid Profitability Concerns and Strategic Initiatives
- Medtronic sees Q1 EPS $1.22-$1.24, consensus $1.32
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue